NEW YORK (Reuters Health) - The results of a small phase II trial suggest that stereotactic body radiotherapy (SBRT), which involves a higher dose but shorter course than standard external beam radiotherapy, is a safe and effective treatment for localized prostate cancer.
"There is great enthusiasm in reducing the length of treatment for prostate cancer while also possibly improving its effectiveness, and these early results are very promising for men with early-stage prostate cancer," lead author Dr. Christopher King, from Stanford University School of Medicine, California, said in a statement.
The findings, reported in the International Journal of Radiation, Oncology, Biology, Physics for March 15, come from a study of 41 men who received a 7.25-Gy daily dose of image-guided SBRT for 5 days delivered with the CyberKnife (Accuracy Inc., Sunnyvale, California).
....
While the findings are encouraging, Dr. King acknowledged that longer follow-up of these patients is needed. "It can often take as long as 10 years to see late side effects and recurrences, so we will have to monitor these men closely and cautiously pursue these treatments further before we can confidently say that SBRT is as good as other proven prostate cancer treatments."
Posts
No comments:
Post a Comment